Universal SARS-CoV-2 RT-qPCR admission screening over 21 months in a German tertiary care hospital: detection of asymptomatic infections Authors: Isabella Eiter, Till Gallasch, Sören Krüger, Michael Eisenmann, Vera Rauschenberger, Anna Höhn, Sina Ebert, Kerstin Knies, Christiane Prifert, Benedikt Weißbrich, Lars Dölken, Stefanie Kampmeier, Isabell Wagenhäuser, Manuel Krone Published: 2026 ABSTRACT Numerous nosocomial infections were observed in hospitals and other healthcare facilities during the COVID-19 pandemic, largely attributed to asymptomatic or pre-symptomatic carriers. SARS-CoV-2 screening data at admission of all hospitalised patients and accompanying persons of a tertiary-care hospital in Germany was included from 1 April 2020 to 31 December 2021. The first oropharyngeal swab of each newly admitted individual was tested for SARS-CoV-2 RNA using reverse transcription polymerase chain reaction (RT-qPCR). The overall testing costs and the costs per positively tested individual were analysed. Out of 111,271 screened individuals, 705 (0.6%) tested positive for SARS-CoV-2 by RT-qPCR. Among these, 236 cases (0.2%) had not been previously diagnosed and were identified through RT-qPCR admission screening. Of the newly detected cases,110 (0.1%) were asymptomatic without any known positive contact history. The specificity of RT-qPCR in screening use was 99.997% (95% CI 99.992–99.999%). The mean testing costs of identifying one SARS-CoV-2-positive individual through admission screening was €8,082.87. Long-term universal RT-qPCR admission screening detected a substantial number of otherwise unidentified SARS-CoV-2-positive individuals, proving its value as a infection control tool with an excellent specificity in screening use during the COVID-19 pandemic. This strategy represents an important lesson learned from the pandemic and may serve as a valuable infection control tool for future pandemics or seasonal pathogen surges.Supplementary InformationThe online version contains supplementary material available at 10.1186/s12879-026-14122-8. Introduction Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) caused the COVID-19 pandemic, resulting in over seven million deaths worldwide as of 29 June 2025 [1]. The first two years were characterised by constant changes in the global epidemiological and virological landscape. Emerging variants, such as the Alpha and Delta variants of concern (VOCs), exhibited significantly higher transmission rates, with increases of 43% to 90% [2] and 40% to 60% [3, 4] respectively compared to the previous variants. This dynamic scenario required stringent protective measures in hospitals to manage the unpredictable risks associated with these evolving viral strains. Currently, the SARS-CoV-2 pandemic has transitioned to an endemic phase [5]. It became essential to detect asymptomatically SARS-CoV-2-infected individuals entering hospitals to prevent nosocomial infections. There have been numerous reports on nosocomial outbreaks causing evitable health implications among the nosocomially infected patients [6]. The proportion of asymptomatic SARS-CoV-2 infections is estimated to be up to 40% [7]. However, as these individuals might also expose high viral load levels, they can be just as infectious as symptomatic individuals [8]. RT-qPCR is the gold standard for diagnosing SARS-CoV-3 infection due to its high sensitivity and specificity, accurately detecting viral RNA even in asymptomatic carriers and individuals with low viral loads. In contrast, SARS-CoV-2 Rapid Antigen Tests (RDTs), though faster, often lack the sensitivity to detect the virus in individuals with lower viral loads or early-stage infections [9]. Despite their convenience and shorter turnaround time, RDTs may yield false negatives, leading to potential transmission of the virus if infected individuals are mistakenly identified as negative [10]. Evidence to date lacks comprehensive evidence on RT-qPCR screening data for large cohorts of individuals across both low and high incidence periods or the influence of the predominance of different evolving SARS-CoV-2 virus variants of concern (VOCs) [11]. Previous evaluations of universal SARS-CoV-2 RT-qPCR testing upon admission have typically involved smaller study cohorts and shorter study durations, like Schreiber et al. with 21,508 admission screenings over a 44-week period, or Scheier et al. with 2,807 screened patients over a 24-day period in April 2020. These studies identified the high proportion of asymptomatic cases which were only detected through the universal testing [12–14]. The relevance of assessing the cost-effectiveness of RT-qPCR testing for COVID-19 lies in its profound implications for public health policy, resource allocation, and healthcare decision-making. By evaluating the economic efficiency of RT-qPCR testing compared to alternative diagnostic approaches, healthcare administrators can prioritise investments in testing infrastructure that yield the greatest public health impact within constrained budgets. Furthermore, cost-effectiveness analyses help identify strategies to optimise testing protocols, processes and test accessibility, thereby maximising the benefits of testing initiatives while minimising financial burdens on healthcare systems and individuals [15]. Ultimately, a comprehensive understanding of the cost-effectiveness of RT-qPCR testing is essential for designing evidence-based SARS-CoV-2 testing strategies that effectively mitigate transmission, safeguard public health, and promote sustainable resource utilisation in the face of future pandemic challenges. The aim of this study is to evaluate the general effectiveness, the costs per detected case, and the specificity of a universal SARS-CoV-2 admission screening by RT-qPCR over a period of 21 months, covering different COVID-19 pandemic phases including several SARS-CoV-2 VOCs. Methods Study setting On 26 March 2020, a comprehensive RT-qPCR testing strategy was implemented at a German tertiary care hospital with a bed capacity of 1,438, which treated 572,442 cases in 2020 and 611,054 cases in 2021. Every newly admitted patient and any accompanying persons underwent SARS-CoV-2 admission screening by RT-qPCR and additionally completed the local COVID-19 questionnaire, which assessed symptoms and potential prior contact with SARS-CoV-2-infected individuals. The questionnaire is provided in the Supplementary Materials in its original version as well as in an English translation. Staff compliance with the admissions screening protocol was high with approximately 90% of the patients undergoing RT-qPCR screening according to an interim analysis of the first two months of the study [12]. The hospital’s catchment area is defined as Lower Franconia, a region in the north of Bavaria, to which the used SARS-CoV-2 incidence data as reference refers [16]. Throughout the 21-month study period, several SARS-CoV-2 VOCs were prevalent. Initially, wild-type SARS-CoV-2 was dominating, followed by the the Alpha VOC in March 2021, and subsequently, the Delta VOC becoming predominant in June 2021. Towards the end of the study period, in December 2021, the Omicron VOC began to surface, albeit with only limited cases identified [17]. Study design and data collection For patients and accompanying persons entering the hospital between 1 April 2020 and 31 December 2021, the first oropharyngeal swab or lower respiratory tract sample (sputum, tracheal aspirate, bronchoalveolar lavage fluid) collected from two days before up to two days after admission was included in the analysis. RT-qPCR testing and VOC allocation Detection of SARS-CoV-2 and determination of the Cycle threshold (Ct) values were performed using different RT-qPCR test kits in the hospital’s virological department [18]: MagNaPure 96 / 7500 Real-Time PCR System / FTD SARS-CoV-2-PCR (target N/ORF1ab-gene, Roche Diagnostics, Rotkreuz, Switzerland / Thermo Fisher Scientific, Waltham MA, USA / Siemens Healthineers, München, Germany).NeuMoDx™ (target N/Nsp2-gene, Qiagen, Hilden, Germany).Alinity m (target RdRp/N-gene, Abbott Laboratories, Abbott Park IL, USA).QIAstat-Dx® (target RdRp/E-gene, Qiagen).Xpert® Xpress SARS-CoV-2/Flu/RSV (target E/N2-gene, Cepheid, Sunnyvale CA, USA).cobas® SARS-CoV-2 (target ORF1ab/E-gene, Roche Diagnostics). MagNaPure 96 / 7500 Real-Time PCR System / FTD SARS-CoV-2-PCR (target N/ORF1ab-gene, Roche Diagnostics, Rotkreuz, Switzerland / Thermo Fisher Scientific, Waltham MA, USA / Siemens Healthineers, München, Germany). MagNaPure 96 / 7500 Real-Time PCR System / FTD SARS-CoV-2-PCR (target N/ORF1ab-gene, Roche Diagnostics, Rotkreuz, Switzerland / Thermo Fisher Scientific, Waltham MA, USA / Siemens Healthineers, München, Germany). NeuMoDx™ (target N/Nsp2-gene, Qiagen, Hilden, Germany). NeuMoDx™ (target N/Nsp2-gene, Qiagen, Hilden, Germany). Alinity m (target RdRp/N-gene, Abbott Laboratories, Abbott Park IL, USA). Alinity m (target RdRp/N-gene, Abbott Laboratories, Abbott Park IL, USA). QIAstat-Dx® (target RdRp/E-gene, Qiagen). QIAstat-Dx® (target RdRp/E-gene, Qiagen). Xpert® Xpress SARS-CoV-2/Flu/RSV (target E/N2-gene, Cepheid, Sunnyvale CA, USA). Xpert® Xpress SARS-CoV-2/Flu/RSV (target E/N2-gene, Cepheid, Sunnyvale CA, USA). cobas® SARS-CoV-2 (target ORF1ab/E-gene, Roche Diagnostics). cobas® SARS-CoV-2 (target ORF1ab/E-gene, Roche Diagnostics). Throughout the study period, the RT-qPCR tests employed were periodically reviewed and adapted by the manufacturers to account for the emergence of new VOCs [19]. The VOC of each sample was determined by melting curve analyses from 3 February 2021 on if it was technically possible. All positive samples before 26 January 2021 were considered to be wild-type SARS-CoV-2 as it was predominant with more than 90% share of the SARS-CoV-2 infections in Germany at that time [17]. Of the 705 positive test results, 602 (85.4%) tests were conducted on the same day as the sample was collected, while 89 (12.6%) tests were evaluated the following day. Additionally, in 14 (2.0%) cases, these were patients transferred from other hospitals who had already been diagnosed as SARS-CoV-2-positive, meaning they were already known to be infected at the time of transfer. RT-qPCR test specificity was determined through follow-up testing and the lack of detectable virus in the subsequently collected probes. Combined questionnaire Questionnaires implemented in the hospital’s information system (HIS) SAP ERP 6.0 (Systemanalyse Programmentwicklung, Walldorf, Germany) containing information on a known SARS-CoV-2 infection, reported symptoms and positive contact history to SARS-CoV-2 infected persons were mandatory for all patients and accompanying persons on admission to assess the risk of a SARS-CoV-2 infection. The information was given by the patient, if possible. Otherwise, information was obtained from accompanying persons. The following symptoms were defined as typical symptoms of a SARS-CoV-2 infection: fever, cough, dyspnoea, fatigue, muscle or body aches, headache, new loss of taste or smell, sore throat, congestion or runny nose, nausea or vomiting, and diarrhoea [20]. The questionnaires were retrieved from the HIS and were analysed for all persons positive in the admission RT-qPCR. Data validation To validate the quality of the information in the questionnaire, data on symptoms and contact history was additionally assessed manually by retrospectively analysing patient files from all included individuals tested positive by RT-qPCR. COVID-19 vaccination Individuals were considered fully vaccinated on day 15 after receiving the second dose in a homologous or heterologous two dose COVID-19 vaccine series with the following vaccines: BNT162b2mRNA (Comirnaty, BioNTech/Pfizer, Mainz/Germany, New York/USA).mRNA-1273 (Spikevax, Moderna, Cambridge/USA).ChAdOx1-S nCoV-19 (AZD1222) (Vaxzevria, Oxford University and AstraZeneca, Cambridge/England, Oxford/England). BNT162b2mRNA (Comirnaty, BioNTech/Pfizer, Mainz/Germany, New York/USA). BNT162b2mRNA (Comirnaty, BioNTech/Pfizer, Mainz/Germany, New York/USA). mRNA-1273 (Spikevax, Moderna, Cambridge/USA). mRNA-1273 (Spikevax, Moderna, Cambridge/USA). ChAdOx1-S nCoV-19 (AZD1222) (Vaxzevria, Oxford University and AstraZeneca, Cambridge/England, Oxford/England). ChAdOx1-S nCoV-19 (AZD1222) (Vaxzevria, Oxford University and AstraZeneca, Cambridge/England, Oxford/England). or two weeks after receiving a single dose vaccine: Ad26.COV2.S (COVID-19 Vaccine Janssen, Johnson & Johnson, Beerse/Belgium). Ad26.COV2.S (COVID-19 Vaccine Janssen, Johnson & Johnson, Beerse/Belgium). Ad26.COV2.S (COVID-19 Vaccine Janssen, Johnson & Johnson, Beerse/Belgium). Only vaccines approved by the European Medicines Agency (EMA) at the time of the study were considered [21]. In the study, patients and accompanying individuals were categorised as having attained basic COVID-19 immunisation only if they had completed their vaccination. Hybrid immunisation through natural infection and vaccination was not considered, as this immunisation status could not be reliably traced. Individuals who received one of two doses in a two dose vaccine series were considered incompletely vaccinated. There was one case with two vaccine doses of the COVID-19 Vaccine (Vero Cell), Inactivated, CoronaVac (SinoVac Biotech, Beijing/P.R.China) which was not an EMA approved vaccine at the time of admission, who was consecutively categorised as unvaccinated in this study [21]. Classification of the positively tested study population Positively tested individuals, categorised into the following groups: Previously known SARS-CoV-2 infection: individuals with a known, laboratory-confirmed SARS-CoV-2 infection before admission.Recovered from previous SARS-CoV-2 infection: individuals with a documented previous SARS-CoV-2 infection who had clinically recovered before admission.Newly detected SARS-CoV-2 infection: individuals whose SARS-CoV-2 infection was first identified through the admission RT-qPCR screening. Previously known SARS-CoV-2 infection: individuals with a known, laboratory-confirmed SARS-CoV-2 infection before admission. Previously known SARS-CoV-2 infection: individuals with a known, laboratory-confirmed SARS-CoV-2 infection before admission. Recovered from previous SARS-CoV-2 infection: individuals with a documented previous SARS-CoV-2 infection who had clinically recovered before admission. Recovered from previous SARS-CoV-2 infection: individuals with a documented previous SARS-CoV-2 infection who had clinically recovered before admission. Newly detected SARS-CoV-2 infection: individuals whose SARS-CoV-2 infection was first identified through the admission RT-qPCR screening. Newly detected SARS-CoV-2 infection: individuals whose SARS-CoV-2 infection was first identified through the admission RT-qPCR screening. Cases identified through the admission screening were further characterised as follows: Symptomatic: individuals presenting with at least one symptom compatible with COVID-19 at admission.Asymptomatic: individuals without COVID-19-related symptoms at the time of testing.Pre-symptomatic: individuals without symptoms at admission who developed COVID-19-compatible symptoms during follow-up. Follow-up information on symptom development was only available for individuals who remained under clinical observation.Previous exposure: documented close contact with a SARS-CoV-2-positive individual before admission.No previous exposure: no known contact with a SARS-CoV-2-positive individual.Missed indicators of infection: individuals in whom symptoms or contact history were not documented or incorrectly reported before screening, including emergency admissions in whom questionnaire assessment was not feasible.False-positive result: positive RT-qPCR results that could not be confirmed by follow-up testing and subsequent clinical assessment. Symptomatic: individuals presenting with at least one symptom compatible with COVID-19 at admission. Symptomatic: individuals presenting with at least one symptom compatible with COVID-19 at admission. Asymptomatic: individuals without COVID-19-related symptoms at the time of testing. Asymptomatic: individuals without COVID-19-related symptoms at the time of testing. Pre-symptomatic: individuals without symptoms at admission who developed COVID-19-compatible symptoms during follow-up. Follow-up information on symptom development was only available for individuals who remained under clinical observation. Pre-symptomatic: individuals without symptoms at admission who developed COVID-19-compatible symptoms during follow-up. Follow-up information on symptom development was only available for individuals who remained under clinical observation. Previous exposure: documented close contact with a SARS-CoV-2-positive individual before admission. Previous exposure: documented close contact with a SARS-CoV-2-positive individual before admission. No previous exposure: no known contact with a SARS-CoV-2-positive individual. No previous exposure: no known contact with a SARS-CoV-2-positive individual. Missed indicators of infection: individuals in whom symptoms or contact history were not documented or incorrectly reported before screening, including emergency admissions in whom questionnaire assessment was not feasible. Missed indicators of infection: individuals in whom symptoms or contact history were not documented or incorrectly reported before screening, including emergency admissions in whom questionnaire assessment was not feasible. False-positive result: positive RT-qPCR results that could not be confirmed by follow-up testing and subsequent clinical assessment. False-positive result: positive RT-qPCR results that could not be confirmed by follow-up testing and subsequent clinical assessment. Within the group of individuals with external RT-qPCR SARS-CoV-2 diagnosis, a significant portion comprised patients transferred from other medical facilities to the tertiary care hospital. Individuals who were asymptomatic or pre-symptomatic during testing, regardless of their contact history with a SARS-CoV-2 infected person were classified as the confirmed asymptomatic cohort. False positive cases and those with missed indicators of SARS-CoV-2 infection were excluded. Comparison of screening positivity with regional incidence For the comparison to the catchment area’s SARS-CoV-2 incidences, case numbers were obtained from the Robert Koch-Institute [22]. Cost analysis The costs of the RT-qPCR assays were calculated with the German national cost assessment standard “Einheitlicher Bewertungsmaßstab (EBM)” for national billing of medical services (Table 1) [23]: Table 1Variation in testing costs depending on the billing period according to the respective reimbursement agreements [24, 25] time period costs per test 1 April 2020–14 May 2020 €59.00 15 May 2020–16 June 2020 €63.00 17 June 2020–30 June 2021 €52.50 1 July 2021–31 December 2021 €45.50 Table 1Variation in testing costs depending on the billing period according to the respective reimbursement agreements [24, 25] time period costs per test 1 April 2020–14 May 2020 €59.00 15 May 2020–16 June 2020 €63.00 17 June 2020–30 June 2021 €52.50 1 July 2021–31 December 2021 €45.50 Variation in testing costs depending on the billing period according to the respective reimbursement agreements [24, 25] As a comparator, a cost-per-case analysis was performed for RDTs as an hypothetical, alternative diagnostic strategy, based on the RDT sensitivity in screening use observed in the parallel testing conducted at the study centre and reported previously [26]. Analyses were performed using the obtained overall RDT sensitivity (34.5%). Reimbursement based on the national COVID-19 testing regulation was amounted to €15.00 throughout the study period [27–30]. Statistics All statistical calculations were done using Microsoft Excel, Version 2021 (Redmond, Washington, United States). The relationship between the incidences in Lower Franconia [22] (the study site`s catchment area) and the proportion tested positive of the tertiary care hospital was investigated using Pearson`s correlation coefficient matrix. P-values < 0.05 were considered as statistically significant. Results Study enrolment Over the 21-months study period, 111,271 individuals (102,848 patients (92.4%); 8,423 accompanying persons (7.6%)) underwent RT-qPCR admission screening. Overall, 705 (0.6%) individuals were tested positive for SARS-CoV-2 (0.6%), whereas 110,566 (99.4%) tested negative. Of the 705 positive cases, 681 (96.6%) were patients, 24 (3.4%) accompanying persons. Three positive screening RT-qPCR results were classified as false positives based on follow-up testing and clinical assessment, corresponding to a screening specificity of 99.997% (95% CI 99.992–99.999%; Fig. 1). Of the 705 individuals who tested positive, 437/705 (62.0%) had a pre-known SARS-CoV-2 infection and were in isolation on admission, 32/705 (4.5%) had recovered symptomatically from their prior SARS-CoV-2 infection and were not in isolation at the time of admission. The remaining 236/705 (33.5%) were initially diagnosed with a SARS-CoV-2 infection at screening, of which 114 (48.3%) were female and 122 (51.7%) were male. Median age of the positively tested patients and accompanying persons was 60.7 (IQR: 43.9–74.6) years. The cases of female sex made up 42.8% of the positively tested with 302 cases and with a median age of 60.1 (IQR: 35.2–77.4) years. The cases of male sex made up 57.2% with 403 cases and had a median age of 61.9 (IQR: 50.8–73.9) years. Characterisation of the positively tested individuals COVID-19 symptoms Of the 236 individuals initially identified as SARS-CoV-2-positive through the RT-qPCR admission screening, 92/236 (39.0%) exhibited typical COVID-19 symptoms, whereas 144/236 (61.0%) were asymptomatic at the time of testing. Among the asymptomatic individuals, 18/144 (12.5%) were presymptomatic and developed symptoms after screening. The average number of patients or accompanying persons needed to test to detect an unanticipated infection was 830. Fig. 1SARS-CoV-2 RT-qPCR admission testing results from 1 April 2020 to 31 December 2021. Stratification of the study cohort by reported SARS-CoV-2 infection, contact history and symptoms (n = 111,271) in absolute and relative numbers. The relative values at each level are always referenced to the parent value in the level above SARS-CoV-2 RT-qPCR admission testing results from 1 April 2020 to 31 December 2021. Stratification of the study cohort by reported SARS-CoV-2 infection, contact history and symptoms (n = 111,271) in absolute and relative numbers. The relative values at each level are always referenced to the parent value in the level above COVID-19 vaccination status Vaccination status was documented in 571/705 (81.0%) of the positively tested individuals: 100/571 (17.5%) were fully vaccinated against COVID-19, 26/571 (4.6%) were incompletely vaccinated, and 445/571 (77.9%) were unvaccinated. Out of the fully vaccinated, vaccine data was available for 90 (90.0%): 88/90 (97.8%) had undergone homologous or single-dose vaccination with Ad26.COV2.S, 2/90 (2.2%) individuals had a heterologous vaccination regimen. Within the cohort of homologous vaccination, 60/77 (77.9%) individuals received two doses of BNT162b2mRNA, 12/77 (15.6%) two doses of ChAdOx1-S nCoV-19 (AZD1222), and 5/77 (6.5%) two doses of mRNA-1273. Ad26.COV2.S as single-dose vaccine was administered to 11 individuals. The two heterologous vaccinated individuals were administered ChAdOx1-S nCoV-19 (AZD1222) for the first dose, followed by either BNT162b2mRNA or mRNA-1273 for the second. Characterisation of the RT-qPCR-detected asymptomatic cases RT-qPCR admission screening detected 110 (0.1%) asymptomatic SARS-CoV-2-positive individuals that had no known previous exposure to SARS-CoV-2 infected persons and that were hence only detected through the testing procedure. This group was defined as the RT-qPCR-detected asymptomatic cohort, which comprised 97/110 (88.2%) patients and 13/110 (11.8%) accompanying persons. The median age of the 110 individuals in the asymptomatic cohort was 54.2 (IQR: 32.0-69.9) years, while the median age of the other 592 positively tested individuals was 61.9 (IQR: 47.5–75.2) years. There were 55 (50.0%) male individuals with a median age of 56.4 (IQR: 34.1–69.9) years and 55 (50.0%) female with a median age of 39.2 (IQR: 30.7–69.9) years among this asymptomatic cohort. Among the 110 asymptomatic individuals 14 were children and adolescents with a median age of 5.4 (IQR: 1.3–11.7) years. COVID-19 vaccination status was documented in 100/110 (90.9%) of the RT-qPCR-detected asymptomatic cohort: 30/100 (30.0%) were fully vaccinated against SARS-CoV-2, 3/100 (3.0%) were incompletely vaccinated and 67/100 (67.0%) were unvaccinated. Of the 30 fully vaccinated individuals, 19 (63.3%) had received BNT162b2 mRNA, 4 (13.3%) had received mRNA-1273, 4 (13.3%) had received ChAdOx1-S nCoV-19 (AZD1222), and 3 (10.0%) had received Ad26.COV2.S. All incompletely vaccinated individuals had received a single dose of BNT162b2mRNA. Dynamics in the hospital’s incidence rate The median incidence rate in Lower Franconia over the study period was 274 (IQR: 68–495) per 100,000 of the population. The median proportion tested positive in the tertiary care hospital was 638 (IQR: 151-1,074) per 100,000. There is a significant very strong correlation between the incidences in Lower Franconia and the proportion tested positive of the tertiary care hospital (r = 0.81; p < 0.00001; Fig. 2). Fig. 2Comparison of the monthly SARS-CoV-2 incidence in Lower Franconia and the proportion tested positive in the tertiary care hospital. The line graph (turquoise) illustrates the absolute fluctuation in the proportion of positive tests within the tertiary care hospital, aligning with the trend observed in the bar chart (blue) representing incidences in Lower Franconia. Instances of reduced incidence in Lower Franconia corresponded with decreased proportions of positive tests in the study centre, evident during the months of June, July, August, and September of 2020, as well as June, July, and August of 2021. Conversely, an increase in the proportion of positive tests coincided with higher incidences in Lower Franconia, notably during the months of November and December of 2020, April of 2021, and November and December of 2021 [17] Comparison of the monthly SARS-CoV-2 incidence in Lower Franconia and the proportion tested positive in the tertiary care hospital. The line graph (turquoise) illustrates the absolute fluctuation in the proportion of positive tests within the tertiary care hospital, aligning with the trend observed in the bar chart (blue) representing incidences in Lower Franconia. Instances of reduced incidence in Lower Franconia corresponded with decreased proportions of positive tests in the study centre, evident during the months of June, July, August, and September of 2020, as well as June, July, and August of 2021. Conversely, an increase in the proportion of positive tests coincided with higher incidences in Lower Franconia, notably during the months of November and December of 2020, April of 2021, and November and December of 2021 [17] Virus variant predomination Among the positively tested cohort (705 cases) there were 304/705 (43.1%) cases of wild-type SARS-CoV-2, 122/705 (17.3%) Alpha VOC, 1/705 (0.1%) Beta VOC, 216 (30.6%) Delta VOC, 2 (0.3%) Omicron VOC, and 60 (8.5%) cases of undetermined VOC (Fig. 3). Due to low viral load no VOC determination was possible for 60/705 (8.5%) of the positively tested. The Omicron VOC just started to exceed the other SARS-CoV-2 VOCs in the beginning of 2022 so it was not yet represented as a predominant VOC in Germany in 2021 [31]. Fig. 3VOC prevalence over the course of 21 months of the universal RT-qPCR testing, measured as the share of all RT-qPCR positive individuals, excluding false positive individuals VOC prevalence over the course of 21 months of the universal RT-qPCR testing, measured as the share of all RT-qPCR positive individuals, excluding false positive individuals Costs of testing Over the entire study period of 21 months, the total costs for testing of all 111,271 screened patients and accompanying persons amounted to €5,698,422.50 (Table 2). In total, the testing costs to detect one SARS-CoV-2 infected person was €8,082.87 (Fig. 4). In comparison, an RDT-based screening strategy would have incurred total costs of €1,669,065.00. Based on the previously observed sensitivity in screening use at the study site of 34.5% [26], the cost of detecting one SARS-CoV-2-positive individual by RDT would have been €6,868.58. Fig. 4Monthly RT-qPCR testing costs, positive cases, and testing cost per positive individual. The totoal RT-qPCR testing costs in € of all 111,271 screened patients and accompanying persons are displayed in salmon-coloured bars, the absolute number RT-qPCR positive cases as a grey line and the testing costs per positively tested individual in orange bars Monthly RT-qPCR testing costs, positive cases, and testing cost per positive individual. The totoal RT-qPCR testing costs in € of all 111,271 screened patients and accompanying persons are displayed in salmon-coloured bars, the absolute number RT-qPCR positive cases as a grey line and the testing costs per positively tested individual in orange bars Table 2RT-qPCR testing costs by time period according to the EBM (Einheitlicher Bewertungsmaßstab) [23] time period costs per testtotal costs 1 April 2020–14 May 2020 €59.00€373,470.00 15 May 2020–16 June 2020 €63.00€318,402.00 17 June 2020–30 June 2021 €52.50€3,462,690.00 1 July 2021–31 December 2021 €45.50€1,543,860.50 1 April 2020–31 December 2021 5,698,422.50Total testing costs of all 111,271 screened patients and accompanying persons, calculated with the individual testing costs and the number of tests conducted during these time periods and the entire study period Table 2RT-qPCR testing costs by time period according to the EBM (Einheitlicher Bewertungsmaßstab) [23] time period costs per testtotal costs 1 April 2020–14 May 2020 €59.00€373,470.00 15 May 2020–16 June 2020 €63.00€318,402.00 17 June 2020–30 June 2021 €52.50€3,462,690.00 1 July 2021–31 December 2021 €45.50€1,543,860.50 1 April 2020–31 December 2021 5,698,422.50Total testing costs of all 111,271 screened patients and accompanying persons, calculated with the individual testing costs and the number of tests conducted during these time periods and the entire study period RT-qPCR testing costs by time period according to the EBM (Einheitlicher Bewertungsmaßstab) [23] Total testing costs of all 111,271 screened patients and accompanying persons, calculated with the individual testing costs and the number of tests conducted during these time periods and the entire study period Discussion Overall, 42% of the newly detected SARS-CoV-2 infections by universal RT-qPCR admission screening could have been identified as being at risk based on typical COVID-19 symptoms or a positive contact history. However, most infections would have remained undetected without universal RT-qPCR admission screening. Given that a substantial portion of SARS-CoV-2 transmissions originates from pre- or asymptomatic individuals exposing viral load levels comparable to symptomatic individuals [32, 33] symptom-based infection control measures alone were insufficient during the pandemic. In addition, RT-qPCR demonstrated an excellent screening specificity of 99.997%, with only three false-positive results among more than 111,000 screened individuals. This high specificity minimised unnecessary isolation measures and supports the suitability of RT-qPCR for universal admission screening in healthcare settings to prevent and mitigate further nosocomial infections through prompt identification of pre- and asymptomatic individuals at admission. The high compliance demonstrated by both staff and patients facilitated the successful implementation and execution of the universal testing procedure at the tertiary care hospital throughout the extended study period. Several hospital policies were implemented during the pandemic that significantly shaped the numbers reported in the study. Asymptomatic patients who tested positive for SARS-CoV-2 during the admission screening were often released when outpatient treatment was feasible or if their hospitalisation could be postponed. Another important policy required accompanying persons to undergo testing upon admission. Furthermore, during the peak phases of the pandemic addressed in this study, there were nationwide recommendations to postpone elective procedures. These measures were adopted by the study centre to minimise the risk of infection within hospitals and to ensure adequate hospital capacities for the high need of COVID-19 treatments during the pandemic’s peak periods [34]. Moreover, we found a strong significant correlation between the positivity rate among patients and accompanying individuals at the tertiary care hospital and the incidence rates in the Lower Franconia catchment area [16, 22]. This suggests the potential for forecasting the progression of SARS-CoV-2 infection rates and predicting future incidence trends because data from hospitalised patients or accompanying persons are faster available and analysed compared to the entire population [35]. Over the 21-month study period, universal RT-qPCR admission screening resulted in total testing costs of €5.7 million, corresponding to €8,082.87 per detected SARS-CoV-2-positive individual. While the overall monthly testing costs remained relatively stable due to the consistently high number of admission screenings, the costs per case detected fluctuated markedly and reflected community incidence. Consequently, universal RT-qPCR screening appears to be most appropriate from an economic perspective during periods of high community transmission or when a highly transmissible and clinically relevant pathogen poses a significant risk for nosocomial outbreaks. Conversely, maintaining the same screening intensity during prolonged periods of low incidence results in diminishing returns and should therefore be balanced against alternative infection prevention strategies and available healthcare resources. In comparison, a hypothetical RDT-based admission screening strategy would have resulted in substantially lower overall costs and costs-per-detected case. At first glance, these findings suggest a more favourable screening option. However, applying the previously observed sensitivity of 34.5% [26], an estimated 462 infected individuals would have remained undetected (false-negative result). These missed infections could have resulted in ongoing nosocomial transmission, delayed implementation of infection prevention measures, and subsequent outbreak-related costs that are not captured by a simple comparison of testing expenditures. The obtained costs must be interpreted in the context of the potential downstream clinical and economic consequences that may have been avoided through earlier infection detection, particularly through the identification of asymptomatic and pre-symptomatic individuals. Such avoided costs may include those associated with potential nosocomial transmission or secondary infections among healthcare workers, improved outbreak control, prevention of outbreak-related ward closures, and earlier diagnosis, thereby reducing the risk of more severe disease courses. The costs of COVID-19 treatment increase substantially with disease severity, averaging approximately €10,700 per hospitalised patient and €32,000 to €33,000 for patients requiring invasive intensive care [36–38]. Although the exact costs attributable to nosocomial SARS-CoV-2 infections cannot be determined because of the lack of a standardised accounting system [37], these figures illustrate the potentially substantial economic consequences of hospital-acquired infections. Furthermore, nosocomial outbreaks may undermine public confidence in hospital infection prevention measures and increase fear of healthcare-associated infections, potentially leading patients to delay or avoid seeking necessary medical care. Such delays may result in disease progression and poorer clinical outcomes beyond COVID-19 itself [39]. By reducing the risk of nosocomial transmission, admission screening has the potential to help maintain confidence in the safety of healthcare services and encourage patients to seek medical care without unnecessary delay. The overall economic impact of preventing nosocomial transmission could not be quantified in the present study, as the number of secondary cases that might have resulted from an undetected asymptomatic or pre-symptomatic individual cannot be reliably estimated [40]. Another consequence of nosocomial outbreaks might be the closure of the entire ward by either necessary patient isolation or possible staff infections. This would result in even higher financial losses than the testing costs. Therefore, RT-qPCR testing may entail higher upfront costs, but its cost-effectiveness becomes apparent when considering the broader spectrum of public health benefits and economic savings associated with accurate disease detection and control. At the current state, the COVID-19 pandemic has transitioned COVID-19 endemicity, and SARS-CoV-2 is one of many seasonal acute respiratory infectious pathogens resulting from different factors such as the high vaccination coverage, hybrid immunisation through infection with the Omicron VOC and vaccination [41]. Further, the Omicron VOC was identified to be significantly less severe than the previous dominant Alpha and Delta VOC as well as the wild-type SARS-CoV-2 [42]. The RT-qPCR admission screening policy at the tertiary care hospital has therefore been stopped on 19 May 2023. As the RT-qPCR admission screening has proved to be an efficient infection control tool, it can be reimplemented depending on the epidemiological situation: Emerging SARS-CoV-2 variants including the Omicron VOC subvariants are being tracked and evaluated on their properties, immune evasion mechanisms and associated disease severity [43]. If concerning properties of new VOCs pose a threat or if the incidence and severity of disease increases rapidly, infection control measures such as the universal RT-qPCR admission screening and consecutive isolation measures in hospitals can be quickly reinstalled to ensure stable health care. This adaptive approach is crucial not only for managing SARS-CoV-2 but also for addressing potential future threats posed by other respiratory pathogens such as Influenza or RSV [44]. Importantly, the screening strategy should be tailored to the pathogen(s) responsible for the current outbreak (e.g. SARS-CoV-2, Influenza, or other emerging respiratory pathogens), rather than implementing routine multiplex screening. Universal admission screening should therefore be considered when highly transmissible pathogens with substantial clinical impact pose a risk of nosocomial transmission. Outside these conditions universal testing procedures upon admission are assumed to be not cost-effective. The continuous emergence of new virus variants, such as those from Influenza A, the monkeypox virus, and SARS-CoV-2, also underscores the need for innovative approaches to effectively respond to potential future pandemics [45]. One promising method is the application of artificial intelligence (AI) to detect patterns in positive test results, which could enhance our understanding of risk dynamics, forecast future infection rates, and investigate the correlation between viral load and symptoms. AI-enabled pattern recognition could serve as an early warning mechanism for potential outbreaks. This proactive strategy would enable public health officials to quickly reinstate measures like RT-qPCR testing and questionnaire-based screenings to mitigate virus transmission. For instance, a study by Mangla et al. utilised pre-trained deep learning models to identify COVID-19 cases through chest X-ray images, achieving high accuracy rates, demonstrating how AI can effectively support rapid diagnosis [46]. Our analysis is limited in the following aspects: The results obtained from the study population of 111,271 individuals cannot be directly extrapolated to the general population since individuals who are admitted to the hospital represent a different demographic characterisation compared to healthy individuals. Additionally, older adults are overrepresented in group of hospitalised individuals compared to the broader population. While the compliance rate of staff was approximately 90%, it is essential to acknowledge that compliance was not absolute [12]. This limitation may affect the representativeness of our findings concerning the entire hospital population. Asymptomatic patients who had tested SARS-CoV-2-positive in the admission screening were often discharged if outpatient treatment was possible or the hospitalisation could be postponed. Consequently, follow-up was incomplete for some individuals, and the absence of symptoms could not be confirmed in all initially asymptomatic cases. Some individuals may therefore have been misclassified as asymptomatic instead of presymptomatic. If asymptomatic carriers were missed due to false-negative results, the actual infection rate might be higher than reported. Further, the study design does not allow to determine whether the screening and identification of pre-symptomatic patients, and the resulting earlier diagnosis, also had a positive impact on the clinical course. The symptoms considered typical for COVID-19 could also be attributed to other pathogens. Incorrect documentation of questionnaire data or information about symptoms in the patient’s files may confound the categorisation of positively tested individuals. Vaccination status was only available for SARS-CoV-2-positive individuals and was not systematically recorded for RT-qPCR-negative individuals. Consequently, comparisons of test positivity according to vaccine type or time since vaccination, as well as estimates of vaccine effectiveness, were not possible. Moreover, the limited number of vaccinated SARS-CoV-2-positive individuals did not allow robust subgroup analyses by vaccine type, time since vaccination, or virus variant. SARS-CoV-2 infected individuals may be missed due to incorrect sampling or rarely occurring false negative RT-qPCR results. Additionally, some individuals who tested positive were discharged home when possible, and due to loss to follow-up, we cannot determine whether these cases were indeed false positives. Due to low viral loads, VOC determination was not possible in all samples. The cost-per-detected-case analysis of the RT-qPCR admission screening covers different pandemic phases but only few Omicron VOC infections. RT-qPCR testing costs in this study were estimated based on the EBM guidelines. However, actual costs may differ due to the unique expense profiles of individual laboratories. Additionally, the costs associated with sample transportation and the working hours required for test performance in the lab were not considered. Building on the findings of this study, future research should investigate the long-term outcomes of both patients and accompanying persons identified through admission screening, assess whether early detection influences clinical course and outcomes, evaluate the impact of vaccination status on disease severity, further elucidate the role of accompanying persons in transmission dynamics, and examine the psychological impact of admission screening on both patients and healthcare staff. A cost-effectiveness analysis including avoided nosocomial infections, hospitalisations, outbreak-related costs, and comparisons with alternative screening strategies was beyond the scope of the present study and should be addressed in future health-economic evaluations. Taken together, patient care facilities require in general more cautious infection control mechanisms than other establishments in society to maintain a functioning healthcare system as nosocomial outbreaks and the avoidance of hospitals among the public would lead to an excess mortality. The universal RT-qPCR admission screening proved its effectiveness as an essential infection prevention measure during the SARS-CoV-2 pandemic. This screening method can therefore be applied in potential future pandemics, offering a basis for proactive response strategies. Supplementary Information Below is the link to the electronic supplementary material. Supplementary Material 1 Supplementary Material 1